FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.

被引：0
|
作者：
Lakins, Matthew A. [1 ]
Munoz-Olaya, Jose [1 ]
Veyssier, Christel [1 ]
Jones, Daniel [1 ]
Goodman, Emma [1 ]
Kaka, Quincy [1 ]
Ofoedu, Jennifer [1 ]
Hughes, Robert [1 ]
Gliddon, Daniel [1 ]
Morrow, Michelle [1 ]
Brewis, Neil [1 ]
机构：
[1] F Star Therapeut, Cambridge, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1864
引用
收藏
页数：2
相关论文
共 29 条
  • [1] FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Lakins, Matthew A.
    Koers, Alexander
    Giambalvo, Raffaella
    Munoz-Olaya, Jose
    Hughes, Robert
    Goodman, Emma
    Marshall, Sylwia
    Wollerton, Francisca
    Batey, Sarah
    Gliddon, Daniel
    Tuna, Mihriban
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4154 - 4167
  • [2] A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies
    Garralda, E.
    Melero, I.
    de Velasco, G.
    Moreno, V.
    Oberoi, H. K.
    Shepherd, C.
    Jones, D.
    Lakins, M. A.
    Hurley, P.
    Khambhatwala, S.
    Long, D.
    Kayitalire, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1454 - S1454
  • [3] A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Huang, Po-Lin
    Kan, Hung-Tsai
    Hsu, Ching-Hsuan
    Hsieh, Hsin-Ta
    Cheng, Wan-Chien
    Huang, Ren-Yeong
    You, Jhong-Jhe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [4] Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Po-Lin Huang
    Hung-Tsai Kan
    Ching-Hsuan Hsu
    Hsin-Ta Hsieh
    Wan-Chien Cheng
    Ren-Yeong Huang
    Jhong-Jhe You
    Journal of Translational Medicine, 21
  • [5] Identification and characterization of MCLA-145 (CD137 x PD-L1): a bispecific antibody that requires PD-L1 binding to activate CD137
    Plyte, Simon
    Geuijen, Cecile
    de Kruif, John
    van Loo, Pieter Fokko
    Tacken, Paul
    Zondag-vander Zande, Vanessa
    Klooster, Rinse
    van Maaden, Hans
    Rovers, Erik
    Engels, Steef
    Franzen, Floris
    Basmeleh, Abdul
    Bartelink, Willem
    Throsby, Mark
    Mayes, Patrick
    Nastri, Horacio
    Stewart, Shaun
    Zhou, Jing
    Wang, Steve
    Huang, Chen-yen
    Codamine, Thomas
    Kularni, Ashwini
    bin Lui, Yao
    Mondal, Arpita
    Hall, Leslie
    Kim, Soeon
    Martinez, Marina
    O'brien, Shaun
    Moon, Edmund
    Albelda, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody
    Lakins, M. A.
    Munoz-Olaya, J.
    Jones, D.
    Giambalvo, R.
    Hall, C.
    Knudsen, A.
    Soler, N. Masque
    Pechouckova, S.
    Goodman, E.
    Gradinaru, C.
    Koers, A.
    Marshall, S.
    Wydro, M.
    Wollerton, F.
    Batey, S.
    Gliddon, D.
    Davies, M.
    Morrow, M.
    Tuna, M.
    Brewis, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Tumor-targeted T-cell activation via an investigational PD-L1 x CD137 bispecific molecule
    Berezhnoy, Alexey
    Huang, Ling
    Liu, Daorong
    DiChiara, Jennifer
    Li, Jonathan
    Smith, Douglas
    Rillema, Jill
    Ciccarone, Valentina
    Tamura, James
    Alderson, Ralph
    Diedrich, Gundo
    Bonvini, Ezio
    Moore, Paul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma
    Garralda, Elena
    Oberoi, Arjun
    de Velasco, Guillermo
    Victoria, Ivan
    Pesantez, David
    Eguren Santamaria, Inaki
    Moreno, Victor
    Boni, Valentina
    Cervantes, Andres
    Gambardella, Valentina
    Ciuleanu, Tudor-Eliade
    Bergamino Sirven, Milana
    Rodriguez-Abreu, Delvys
    Alonso, Guzman
    Minea Gales, Laurentia
    Jones, Daniel
    Patki, Abhay
    Ataman, Ozlem
    Melero Bermejo, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Prenen, H.
    Kyi, C.
    Van Lancker, G.
    Patel, S. P.
    Mittag, D.
    Weaver, A.
    Bol, K.
    Stalbovskaya, V.
    Pulini, J.
    Zhou, G.
    Dong, Z.
    Asatiani, E.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436
  • [10] CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
    Puigdelloses, Montserrat
    Garcia-Moure, Marc
    Labiano, Sara
    Laspidea, Virginia
    Gonzalez-Huarriz, Marisol
    Zalacain, Marta
    Marrodan, Lucia
    Martinez-Velez, Naiara
    De la Nava, Daniel
    Ausejo, Iker
    Hervas-Stubbs, Sandra
    Herrador, Guillermo
    Chen, ZhiHong
    Hambardzumyan, Dolores
    Patino Garcia, Ana
    Jiang, Hong
    Gomez-Manzano, Candelaria
    Fueyo, Juan
    Perez de Larraya, Jaime Gallego
    Alonso, Marta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
123